Texas Yale Capital Corp’s Vertex Pharmaceuticals VRTX Stock Holding History

Texas Yale Capital Corp’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.94M	Buy	4,344 +75	+2%	+$35K	0.06%	203
2025 Q4	$1.94M	Buy	4,269 +181	+4%	+$78K	0.06%	209
2025 Q3	$1.6M	Buy	4,088 +120	+3%	+$50.2K	0.05%	220
2025 Q2	$1.77M	Sell	3,968 -125	-3%	-$57.6K	0.06%	199
2025 Q1	$1.98M	Hold	4,093	–	–	0.08%	186
2024 Q4	$1.65M	Sell	4,093 -115	-3%	-$53.3K	0.07%	202
2024 Q3	$1.96M	Hold	4,208	–	–	0.09%	193
2024 Q2	$1.97M	Sell	4,208 -10	-0.2%	-$4.34K	0.09%	176
2024 Q1	$1.76M	Buy	4,218 +439	+12%	+$186K	0.08%	193
2023 Q4	$1.54M	Buy	+3,779	New	+$1.4M	0.07%	201

Other funds holding VRTX

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Texas Yale Capital Corp's VRTX Position: Q1 2026 in Review

Texas Yale Capital Corp increased its Vertex Pharmaceuticals (VRTX) stake by 1.8% in Q1 2026, buying an estimated $35K and bringing the position to 4,344 shares worth $1.94M. The position accounts for 0.06% of the portfolio, ranked #203.

Texas Yale Capital Corp first reported a position in VRTX in Q4 2023 and has held it in 10 quarters since. The position peaked at $1.98M in Q1 2025. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.

Texas Yale Capital Corp held 4,344 shares of Vertex Pharmaceuticals worth $1.94M as of Q1 2026.
Texas Yale Capital Corp bought 75 Vertex Pharmaceuticals shares in Q1 2026, an estimated $35K.
Vertex Pharmaceuticals made up 0.06% of Texas Yale Capital Corp's portfolio in Q1 2026, its #203 holding.
Texas Yale Capital Corp first reported a position in Vertex Pharmaceuticals in Q4 2023 and has held it in 10 quarters since.
Texas Yale Capital Corp's Vertex Pharmaceuticals position peaked at $1.98M in Q1 2025.
1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.

Based on Texas Yale Capital Corp's 13F filing for Q1 2026, filed 4 May 2026.